14.01.2015 • News • Mergers & Acquisitions (M&A) • Artenius Turkpet • Indorama Ventures

Indorama Buys New Polyplex's Turkish PET Plant

In a deal set to close during the first quarter of this year, Thai polyester giant Indorama, world's largest producer of PET packaging resins, plans to acquire a 252,000 t/y production facility in Corlu, Turkey, built by a Turkish offshoot of the India-based global PET film manufacturer Polyplex.

First announced in 2012, the Polyplex PET plant located near Istanbul is believed to have been idle since completion, as the company was reticent to start up in the face of a massively oversupplied market.

In 2014, Indorama acquired a 130,000 t/y PET resin plant in Turkey owned by Artenius Turkpet, a subsidiary of the insolvent erstwhile PET market leader La Seda de Barcelona. With the addition of the Polyplex facility, the Thai group will have capacity for 382,000 t/y of resin in Turkey, making it the region's market leader.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Top-Feature

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.